Dengue: Status of current and under‐development vaccines

@article{Redoni2020DengueSO,
  title={Dengue: Status of current and under‐development vaccines},
  author={Marianna Redoni and Sophie Yacoub and Laura Rivino and Daniele Roberto Giacobbe and Roberto Luzzati and Stefano Di Bella},
  journal={Reviews in Medical Virology},
  year={2020},
  volume={30}
}
Dengue is an emerging mosquito‐borne viral infection with increasing reports of outbreaks. The clinical picture ranges from a benign febrile illness through to severe and potentially fatal manifestations. No specific anti‐viral treatment exists, and therapy only consists of supportive care. During the last three decades, several attempts to develop an effective vaccine have been made. The first dengue vaccine to obtain licensure was Dengvaxia, which was authorized in 2015 and is currently… 
Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Produced in Escherichia coli
TLDR
Advances in this field require high investments that will probably not raise interest from private pharmaceutical companies and, therefore, will require support by international philanthropic organizations and governments of the countries more severely stricken by these viruses.
Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine
TLDR
An overview of the current knowledge about the role of sNS1 in the immunopathogenesis of dengue disease is provided and the potential use of s NS1 in future vaccine development and its potential to improve d Dengue vaccine efficiency are discussed.
Viral Emerging Diseases: Challenges in Developing Vaccination Strategies
TLDR
This review gives an update on the current vaccination strategies for some of the emerging/re-emerging viruses, and discusses challenges and hurdles to overcome for developing efficacious vaccines against future pathogens.
Laboratory Findings in Patients with Probable Dengue Diagnosis from an Endemic Area in Colombia in 2018
TLDR
Whether there is an association between hematological findings and the probability for an NS1-based DENV RDT to detect the DENV NS1 antigen is determined and the hematology parameters that are associated with the diagnosis through each test are described.
Traditional Knowledge to Contemporary Medication in the Treatment of Infectious Disease Dengue: A Review
TLDR
This review includes the existing traditional knowledge on how DENV infects and multiplies in the host cells, conscripting different medicinal plants that obtained bioactive compounds with anti-dengue properties, and the probable mechanism on howBioactive compounds modulate the host immune system during DENV infection.
Comparative Analysis of Emerging Viruses to Inform Development of Safe and Effective Vaccines for COVID-19
TLDR
A systematic analysis of the pathogenesis of four viruses that have emerged as causative agents for endemics in the past decade will enable the understanding the requirements and anticipate challenges in development of novel diagnostics, therapies, and vaccines for COVID-19 pandemic.
Covid‐19 and dengue: Double punches for dengue‐endemic countries in Asia
TLDR
The issue of Covid‐19 and dengue fever misdiagnosis is raised, not only in a clinical setting but also with regards to cross‐reactivity between SARS‐CoV‐2 and DENV antibodies.
Zika virus infection enhances future risk of severe dengue disease
TLDR
This study investigated prospective pediatric cohorts in Nicaragua that experienced sequential DENV1 to -3, Zika (2004 to 2015), Zika (2016 to 2017), and DENV2 (2018 to 2020) epidemics and found that prior immunity to Zika virus increases the risk of severe dengue disease via cross-reacting antibodies.
Complications of Dengue Infection in Admitted Patients at Rehman Medical Institute: A Retrospective Study
TLDR
Among a set of varied symptoms, malaise was the most common clinical presentation, along with 94% fever, and a substantial number of patients suffered from serious complications such as neurological and hemorrhagic conditions along with communal clinical manifestations in Khyber Pakhtunkhwa, Pakistan.
...
1
2
3
...

References

SHOWING 1-10 OF 79 REFERENCES
Dengue vaccine: Global development update.
The first licensed dengue vaccine, CYD-TDV (Dengvaxia®), has received regulatory approval in a number of countries. However, this vaccine has some limitations. Its efficacy against DENV2 was
Dengue vaccines: recent developments, ongoing challenges and current candidates
TLDR
The recent advances in dengue virus vaccine development are reviewed and the challenges associated with the use of these vaccines as a public health tool are briefly discussed.
Working towards dengue as a vaccine-preventable disease: challenges and opportunities
TLDR
The authors believe that the novel strategies for testing and improving the immune response of vaccine candidates in humans will eventually lead to the development of a successful dengue vaccine in future.
Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development
TLDR
Progress is outlined in understanding of mouse mAbs, human m Abs, and polyclonal sera against DENV envelope and precursor membrane proteins, two surface proteins involved in vaccine development, following natural infection; analyses have provided valuable insight into new strategies involving molecular technology to induce more potent neutralizing antibodies and less enhancing antibodies for next-generation dengue vaccine development.
Dengue Fever: Causes, Complications, and Vaccine Strategies
TLDR
Alternative strategies of developing a designed vaccine candidate which does not allow production of enhancing antibodies should be explored, as it may expand the umbrella of efficacy to include infants and naïve individuals.
Dengue: a growing threat requiring vaccine development for disease prevention
TLDR
An update on the dengue global trends and different vaccine strategies in development is proposed, with particular attention paid to up-to-date information on d Dengue transmission and the protective efficacy of newly commercialized tetravalent dengu vaccine Dengvaxia®, as well as the most advanced candidate vaccines in clinical development.
Live Attenuated Tetravalent Dengue Virus Host Range Vaccine Is Immunogenic in African Green Monkeys following a Single Vaccination
TLDR
A live attenuated viral (LAV) vaccine capable of eliciting a strong immune response in African green monkeys (AGMs) in a single dose is generated, and this study suggests that viremia and antibody response in AGMs may be similar to those seen in DENV infection in humans.
Efficacy of a tetravalent dengue vaccine in children in Latin America.
TLDR
The CYD-TDV dengue vaccine was efficacious against V CD and severe VCD and led to fewer hospitalizations for VCD in five Latin American countries where d Dengue is endemic.
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
TLDR
TAK-003 was efficacious against symptomatic dengue in countries in which the disease is endemic and the incidence of serious adverse events was similar in the vaccine group and placebo group.
...
1
2
3
4
5
...